Literature DB >> 15265893

CpG-C immunostimulatory oligodeoxyribonucleotide activation of plasmacytoid dendritic cells in rhesus macaques to augment the activation of IFN-gamma-secreting simian immunodeficiency virus-specific T cells.

Natalia Teleshova1, Jessica Kenney, Jennifer Jones, Jason Marshall, Gary Van Nest, Jason Dufour, Rudolf Bohm, Jeffrey D Lifson, Agegnehu Gettie, Melissa Pope.   

Abstract

There are two principle subsets of dendritic cells (DCs); CD11c(+)CD123(-) myeloid DCs (MDCs) and CD11c(-)CD123(+) plasmacytoid DCs (PDCs). DC activation via TNF-TNFRs (e.g., CD40L) and TLRs (e.g., immunostimulatory oligodeoxyribonucleotides (ISS-ODNs)) is crucial for maximal stimulation of innate and adaptive immunity. Macaque DC biology is being studied to improve HIV vaccines using the SIV macaque model. Using lineage (Lin) markers to exclude non-DCs, Lin(-)HLA-DR(+)CD11c(+)CD123(-) MDCs and Lin(-)HLA-DR(+)CD11c(-)CD123(+) PDCs were identified in the blood of uninfected macaques and healthy macaques infected with SIV or simian-human immunodeficiency virus. Overnight culture of DC-enriched Lin-depleted cells increased CD80 and CD86 expression. IL-12 production and CD80/CD86 expression by MDC/PDC mixtures was further enhanced by CD40L and ISS-ODN treatment. A CpG-B ISS-ODN increased CD80/CD86 expression by PDCs, but resulted in little IFN-alpha secretion unless IL-3 was added. In contrast, a CpG-C ISS-ODN and aldrithiol-2-inactivated (AT-2) SIV induced considerable PDC activation and IFN-alpha release without needing exogenous IL-3. The CpG-C ISS-ODN also stimulated IL-12 release (unlike AT-2 SIV) and augmented DC immunostimulatory activity, increasing SIV-specific T cell IFN-gamma production induced by AT-2 SIV-presenting MDC/PDC-enriched mixtures. These data highlight the functional capacities of MDCs and PDCs in naive as well as healthy, infected macaques, revealing a promising CpG-C ISS-ODN-driven DC activation strategy that boosts immune function to augment preventative and therapeutic vaccine efficacy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15265893     DOI: 10.4049/jimmunol.173.3.1647

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  31 in total

1.  Characterization of plasmacytoid dendritic cells in bone marrow of pig-tailed macaques.

Authors:  R Keith Reeves; Patricia N Fultz
Journal:  Clin Vaccine Immunol       Date:  2007-11-07

2.  A fusion inhibitor prevents spread of immunodeficiency viruses, but not activation of virus-specific T cells, by dendritic cells.

Authors:  I Frank; H Stössel; A Gettie; S G Turville; J W Bess; J D Lifson; I Sivin; N Romani; M Robbiani
Journal:  J Virol       Date:  2008-03-26       Impact factor: 5.103

3.  Nonpathogenesis of simian immunodeficiency virus infection is associated with reduced inflammation and recruitment of plasmacytoid dendritic cells to lymph nodes, not to lack of an interferon type I response, during the acute phase.

Authors:  Laure Campillo-Gimenez; Mireille Laforge; Michèle Fay; Audrey Brussel; Marie-Christine Cumont; Valérie Monceaux; Ousmane Diop; Yves Lévy; Bruno Hurtrel; John Zaunders; Jacques Corbeil; Carole Elbim; Jérôme Estaquier
Journal:  J Virol       Date:  2009-11-25       Impact factor: 5.103

4.  Characterization of virus-responsive plasmacytoid dendritic cells in the rhesus macaque.

Authors:  Eugene Chung; Sheela B Amrute; Kristina Abel; Gunjan Gupta; Yichuan Wang; Christopher J Miller; Patricia Fitzgerald-Bocarsly
Journal:  Clin Diagn Lab Immunol       Date:  2005-03

5.  Tonsillar application of AT-2 SIV affords partial protection against rectal challenge with SIVmac239.

Authors:  Panagiotis Vagenas; Vennansha G Williams; Michael Piatak; Julian W Bess; Jeffrey D Lifson; James L Blanchard; Agegnehu Gettie; Melissa Robbiani
Journal:  J Acquir Immune Defic Syndr       Date:  2009-12-01       Impact factor: 3.731

6.  Plasmacytoid dendritic cell dynamics and alpha interferon production during Simian immunodeficiency virus infection with a nonpathogenic outcome.

Authors:  Ousmane M Diop; Mickaël J-Y Ploquin; Lorenzo Mortara; Abdourahmane Faye; Béatrice Jacquelin; Désirée Kunkel; Pierre Lebon; Cécile Butor; Anne Hosmalin; Françoise Barré-Sinoussi; Michaela C Müller-Trutwin
Journal:  J Virol       Date:  2008-04-02       Impact factor: 5.103

7.  A tonsillar PolyICLC/AT-2 SIV therapeutic vaccine maintains low viremia following antiretroviral therapy cessation.

Authors:  Panagiotis Vagenas; Meropi Aravantinou; Vennansha G Williams; Edith Jasny; Michael Piatak; Jeffrey D Lifson; Andres M Salazar; James L Blanchard; Agegnehu Gettie; Melissa Robbiani
Journal:  PLoS One       Date:  2010-09-21       Impact factor: 3.240

8.  Enhanced in vivo immunogenicity of SIV vaccine candidates with cationic liposome-DNA complexes in a rhesus macaque pilot study.

Authors:  Jeff Fairman; Joseph Moore; Mathieu Lemieux; Koen Van Rompay; Yongzhi Geng; John Warner; Kristina Abel
Journal:  Hum Vaccin       Date:  2009-03-14

9.  A critical role for CD8 T cells in a nonhuman primate model of tuberculosis.

Authors:  Crystal Y Chen; Dan Huang; Richard C Wang; Ling Shen; Gucheng Zeng; Shuyun Yao; Yun Shen; Lisa Halliday; Jeff Fortman; Milton McAllister; Jim Estep; Robert Hunt; Daphne Vasconcelos; George Du; Steven A Porcelli; Michelle H Larsen; William R Jacobs; Barton F Haynes; Norman L Letvin; Zheng W Chen
Journal:  PLoS Pathog       Date:  2009-04-17       Impact factor: 6.823

10.  A macaque model to study vaginal HSV-2/immunodeficiency virus co-infection and the impact of HSV-2 on microbicide efficacy.

Authors:  Federica Crostarosa; Meropi Aravantinou; Onome J Akpogheneta; Edith Jasny; Andrew Shaw; Jessica Kenney; Michael Piatak; Jeffrey D Lifson; Aaron Teitelbaum; Lieyu Hu; Anne Chudolij; Thomas M Zydowsky; James Blanchard; Agegnehu Gettie; Melissa Robbiani
Journal:  PLoS One       Date:  2009-11-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.